Navigation Links
Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer
Date:2/22/2010

MM-121, Merrimack’s lead oncology therapeutic candidate, is an antibody designed to block signaling of ErbB3. This is the first of multiple trials that Merrimack and sanofi-aventis expect to initiate in 2010 as part of a broad Phase 2 clinical development program for MM-121.

Cambridge, Mass. (PRWEB) February 22, 2010 -- Merrimack Pharmaceuticals, Inc. announced today that the first patient has received an initial dose in a Phase 1/2 clinical study combining MM-121 with Tarceva® (erlotinib) in patients with non-small cell lung cancer (NSCLC). This is the first of multiple trials that Merrimack and sanofi-aventis expect to initiate in 2010 as part of a broad Phase 2 clinical development program for MM-121.

MM-121, Merrimack’s lead oncology therapeutic candidate, is an antibody designed to block signaling of ErbB3. Erlotinib is a small molecule targeting the epidermal growth factor receptor (EGFR).

“Our Network Biology analysis of cancer cells indicates that tumors often become resistant to EGFR-targeted therapies by compensating for tumor growth restriction through the ErbB3 receptor,” stated Clet Niyikiza, Ph.D., Senior Vice President of Development at Merrimack. “We believe that this discovery, which has since been confirmed by leading academic laboratories, indicates that MM-121 in combination with Tarceva® could be a powerful treatment for lung cancer patients who no longer respond to EGFR treatment alone.”

The Phase 1/2 study will initially evaluate the human safety and pharmacokinetics (PK) of MM-121 in combination with erlotinib, establish a safe combination regimen, and then inve
'/>"/>

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

0

GOOD

Page: 1 2 3

Related biology technology :

1. Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors
2. Merrimack Pharmaceuticals Raises $60 Million in Private Financing
3. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
4. Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development
5. Merrimack Pharmaceuticals Names Clet Niyikiza, Ph.D. Senior Vice President, Development
6. Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
7. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
8. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer
(Date:5/24/2013)... (PRWEB) May 24, 2013 Bed bug cases ... protect themselves from the looming higher risk of becoming the ... a new bed bug guideline. In the guide, the company ... and avoiding them while traveling. , According to ... an increase of bed bug infestation during summer: the warm ...
(Date:5/24/2013)... 24, 2013 The Oklahoma tornado ... its ravage, the mayor of Moore, one of the heavily ... said a report from cnn.com. Reaching out to also be ... Molderizer and Safe Shield to counter the looming mold problem. ... on May 22, 2013, caused 24 deaths, My Cleaning Products ...
(Date:5/23/2013)... ROCK, Colo. , May 23, 2013 ... diagnostic company focused on obtaining FDA clearance and ... , today announced the pricing of an underwritten public ... related warrants to purchase 3,500,000 shares of its common ... at a combined public offering price of $1.25 per ...
(Date:5/23/2013)... Wis. , May 23, 2013 ... researcher, developer, and marketer of over-the-counter (OTC) medicinal ... its research opinion on the company based on ... , Non-Prescription, All Natural Product to ... the Product Outperforms #1 Prescription Competitor , ...
Breaking Biology Technology:Steps for Getting Rid of Bed Bugs without Using Chemicals and Avoiding Them While Traveling Enumerated by My Cleaning Products in Its Latest Post 2Steps for Getting Rid of Bed Bugs without Using Chemicals and Avoiding Them While Traveling Enumerated by My Cleaning Products in Its Latest Post 3Mayor of Oklahoma-Tornado-Impaired Town Proposes Storm Shelter Bill, My Cleaning Products Offers Complimentary Molderizer and Safe Shield to Help Victim with Looming Mold 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3
... Sept. 30 GeneGo Inc., a leading,provider of ... that they were awarded with a Phase I ... the development of a platform for understanding,the influence ... collaborate with FDA investigator, Jim Kaput Director of ...
... Cell Therapeutics, Inc.,(CTI) (Nasdaq and MTA: CTIC) will ... October 3, 2008. The investor day will provide an ... milestones,for the Company. Additionally, Alessandro Gianni, M.D., Director of ... of Milan,who has authored over 300 publications will be ...
... 29 Verathon Inc. is pleased to,announce that ... prestigious Technology,Fast 50 Program for Washington State, a ... and life sciences companies in the,area by Deloitte, ... which is privately held, ranked 27th on the,list ...
Cached Biology Technology:GeneGo Is Awarded NCI Grant for Development of Systems Biology Database and Tools for Nutrition in Cancer in Collaboration with the FDA 2Cell Therapeutics Provides Details on Investor & Media Day to be Held in Milan, Italy on Friday, October 3, 2008 2Verathon Inc., Maker of BladderScan(R) and GlideScope(R), Ranks in Deloitte's 2008 Washington State Technology 'Fast 50' for 5th Time in Past 7 Years 2Verathon Inc., Maker of BladderScan(R) and GlideScope(R), Ranks in Deloitte's 2008 Washington State Technology 'Fast 50' for 5th Time in Past 7 Years 3
(Date:5/23/2013)... palsy with autologous cord blood. Following a cardiac arrest ... had been in a persistent vegetative state with ... with the cord blood containing stem cells, the symptoms ... to speak simple sentences and to move. "Our findings, ... long-held doubts about the effectiveness of the new therapy", ...
(Date:5/23/2013)... , the team reveal the interplay of brain chemicals ... the Wellcome Trust and BBSRC. , By changing ... our perceptual abilities. While these changes can affect the ... the fidelity of that response. , Lead ... you communicate with others, you can make yourself better ...
(Date:5/22/2013)... (NLST) investigators also conclude that the 20 percent ... tomography (LDCT) versus chest X-ray (CXR) screening previously ... at experienced screening centers in the United States. ... with their patients about the benefits and risks ... in the New England Journal of Medicine ...
Breaking Biology News(10 mins):First successful treatment of pediatric cerebral palsy with autologous cord blood 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 3
... New evidence of how the elevated glucose ... lead to novel strategies for blocking the destruction, Medical ... decreased ability of blood vessels to relax resulted from ... form and function, says Dr. Rita C.Tostes, physiologist in ...
... investigated in a group of piglets. Scientists writing in ... the pathology of the virus, finding that all infected ... after infection and were shedding virus two days after ... from Chulalongkorn University, Bangkok, who infected 22-day old pigs ...
... WI, May 4, 2009--Contrary to the prevailing view, cereal ... soil, not fertilizer. Soils differ considerably in microbial activities ... taken into account if nitrogen fertilizers are to be ... developed for this purpose, and involves estimation of gaseous ...
Cached Biology News:New evidence of how high glucose damages blood vessels could lead to new treatments 2Illinois Soil Nitrogen Test measures microbial nitrogen 2